MCID: SZR001
MIFTS: 63

Sezary's Disease

Categories: Rare diseases, Skin diseases, Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Sezary's Disease

MalaCards integrated aliases for Sezary's Disease:

Name: Sezary's Disease 12 15
Sezary Syndrome 12 76 53 25 55 6 44 73
Sézary Syndrome 53 25 59
Sezary's Lymphoma 53 25
Sezary Erythroderma 25
Sézary Lymphoma 59
Sezary Disease 12

Characteristics:

Orphanet epidemiological data:

59
sézary syndrome
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: <1/1000000 (United States),<1/1000000 (Norway); Age of onset: Adult; Age of death: adult;

Classifications:



Summaries for Sezary's Disease

NIH Rare Diseases : 53 Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell) become cancerous and affect the skin. It is characterized by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes. Other signs and symptoms may include intense itchiness, scaling and peeling of the skin; fever; weight loss; hair loss; outward turning of the eyelids (ectropion); palmoplantar keratoderma; malformation of the nails; and hepatosplenomegaly. The exact cause of Sezary syndrome is currently unknown. Treatment varies based on the signs and symptoms present in each person and the severity of the condition.

MalaCards based summary : Sezary's Disease, also known as sezary syndrome, is related to mycosis fungoides and hematopoietic stem cell transplantation, and has symptoms including pruritus An important gene associated with Sezary's Disease is BCL10 (B Cell CLL/Lymphoma 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Denileukin diftitox and Aprepitant have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are ectropion and dry skin

Wikipedia : 76 Sézary disease is a type of cutaneous lymphoma that was first described by Albert Sézary. The affected... more...

Related Diseases for Sezary's Disease

Diseases related to Sezary's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 mycosis fungoides 32.8 CD28 CTLA4 DPP4 IL2 IL2RA IL5
2 hematopoietic stem cell transplantation 31.5 CTLA4 IFNG IL2
3 cutaneous t cell lymphoma 31.1 IFNG IL2 IL2RA IL4 IL7
4 uveitis 30.9 CTLA4 IFNG IL2RA IL4
5 lymphoma, non-hodgkin, familial 30.6 BCL10 IL2 IL2RA TLR9
6 mycoplasmal pneumonia 11.1 IFNG IL4
7 chronic active epstein-barr virus infection 11.0 CTLA4 IFNG IL2
8 virus associated hemophagocytic syndrome 11.0 IL2 IL4
9 angiostrongyliasis 11.0 IL2 IL4 IL5
10 autoimmune disease of endocrine system 11.0 CTLA4 IFNG IL2
11 eosinophilic fasciitis 11.0 IFNG IL5
12 hyperlucent lung 11.0 IFNG IL2RA IL4
13 microscopic colitis 10.9 IFNG IL2 IL4
14 variola major 10.9 IFNG IL2
15 severe combined immunodeficiency, x-linked 10.9 IL2 IL4 IL7
16 b-cell growth factor 10.9 IFNG IL4 IL7
17 vulvovaginal candidiasis 10.9 IFNG IL2 IL4
18 posterior uveitis 10.9 IFNG IL2 IL2RA
19 intermediate uveitis 10.9 IFNG IL2 IL2RA
20 rheumatoid factor-negative juvenile idiopathic arthritis 10.9 IL2RA STAT4
21 wells syndrome 10.9 IL2 IL2RA IL5
22 pure red-cell aplasia 10.9 IL2 IL2RA TRB
23 onchocerciasis 10.9 IL2 IL4 IL5
24 exanthem 10.9 IL2 TLR9 TNFRSF1B
25 radiculopathy 10.9 IL2RA IL5 IL7
26 autoimmune myocarditis 10.9 IFNG IL2
27 leprosy 3 10.9 IFNG IL2 IL4
28 paranasal sinus disease 10.9 IFNG IL4 IL5
29 tropical spastic paraparesis 10.9 IFNG IL2 IL2RA
30 spondyloarthropathy 10.9 IFNG IL2 IL4
31 allergic conjunctivitis 10.9 IFNG IL4 IL5
32 pulmonary sarcoidosis 10.8 IFNG IL2 IL2RA
33 lichen disease 10.8 IFNG IL4 TLR9
34 cryptococcosis 10.8 IFNG IL4 TLR9
35 graft-versus-host disease 10.8 CD28 IFNG IL2
36 nasal cavity disease 10.8 IL4 IL5 TLR9
37 b-cell expansion with nfkb and t-cell anergy 10.8 CD28 IL2 IL2RA TRB
38 alopecia areata 10.8 CTLA4 IFNG IL2 IL2RA
39 food allergy 10.8 IFNG IL4 IL5
40 myasthenia gravis 10.8 CTLA4 IFNG IL2 IL4
41 nose disease 10.8 IL4 IL5 TLR9
42 opportunistic mycosis 10.8 IFNG IL4 TLR9
43 parasitic helminthiasis infectious disease 10.8 IL4 IL5 TLR9
44 urinary schistosomiasis 10.8 CTLA4 IFNG IL4 IL5
45 human immunodeficiency virus infectious disease 10.8 IFNG IL2 TLR9
46 allergic contact dermatitis 10.8 IFNG IL4 IL5
47 upper respiratory tract disease 10.8 IL4 IL5 TLR9
48 toxic shock syndrome 10.8 IFNG IL2 IL4
49 gastroenteritis 10.8 IFNG IL4 IL5
50 autoinflammation, lipodystrophy, and dermatosis syndrome 10.8 IFNG IL4 IL5

Graphical network of the top 20 diseases related to Sezary's Disease:



Diseases related to Sezary's Disease

Symptoms & Phenotypes for Sezary's Disease

Human phenotypes related to Sezary's Disease:

59 32 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ectropion 59 32 occasional (7.5%) Occasional (29-5%) HP:0000656
2 dry skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0000958
3 edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0000969
4 palmoplantar keratoderma 59 32 frequent (33%) Frequent (79-30%) HP:0000982
5 pruritus 59 32 hallmark (90%) Very frequent (99-80%) HP:0000989
6 erythroderma 59 32 hallmark (90%) Very frequent (99-80%) HP:0001019
7 tremor 59 32 occasional (7.5%) Occasional (29-5%) HP:0001337
8 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
9 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
10 abnormal facial shape 59 32 occasional (7.5%) Occasional (29-5%) HP:0001999
11 abnormality of the pleura 59 32 occasional (7.5%) Occasional (29-5%) HP:0002103
12 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
13 lymphadenopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002716
14 immunodeficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002721
15 skeletal muscle atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0003202
16 irregular hyperpigmentation 59 32 occasional (7.5%) Occasional (29-5%) HP:0007400
17 neoplasm of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0008069
18 nail dystrophy 59 32 frequent (33%) Frequent (79-30%) HP:0008404
19 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
20 abnormal immunoglobulin level 59 32 occasional (7.5%) Occasional (29-5%) HP:0010701
21 cutaneous t-cell lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012192
22 lichenification 59 32 hallmark (90%) Very frequent (99-80%) HP:0100725
23 gangrene 59 32 occasional (7.5%) Occasional (29-5%) HP:0100758
24 abnormality of the face 59 Frequent (79-30%)
25 lymphoma 59 Very frequent (99-80%)
26 abnormality of lymphocytes 59 Very frequent (99-80%)

UMLS symptoms related to Sezary's Disease:


pruritus

MGI Mouse Phenotypes related to Sezary's Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 TLR9 TNFRSF1B IL2 STAT4 BCL10 IL2RA
2 endocrine/exocrine gland MP:0005379 10.06 STAT4 TNFRSF1B IL2 BCL10 IL2RA CD28
3 digestive/alimentary MP:0005381 10.02 TLR9 TNFRSF1B IL2 IL2RA CD28 CTLA4
4 homeostasis/metabolism MP:0005376 9.97 STAT4 TLR9 TNFRSF1B IFNGR2 PLS3 IL2
5 immune system MP:0005387 9.8 TLR9 TNFRSF1B PLS3 IL2 STAT4 BCL10
6 respiratory system MP:0005388 9.17 TNFRSF1B IL2 IL2RA CTLA4 IL4 IL5

Drugs & Therapeutics for Sezary's Disease

Drugs for Sezary's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 354)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Not Applicable 173146-27-5
2
Aprepitant Approved, Investigational Phase 4,Not Applicable 170729-80-3 151165 6918365
3
Fosaprepitant Approved Phase 4,Not Applicable 172673-20-0 219090
4
Substance P Investigational Phase 4,Not Applicable 33507-63-0 44359816
5 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 neurokinin A Phase 4,Not Applicable
11 Neurokinin-1 Receptor Antagonists Phase 4,Not Applicable
12
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
13
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
14
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 23214-92-8 31703
15
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
16
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
17
Ofloxacin Approved Phase 3 82419-36-1 4583
18
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
19
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
20
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
21
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
22
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
23
Bexarotene Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 153559-49-0 82146
24
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
25
Methoxsalen Approved Phase 3,Phase 2,Phase 1,Not Applicable 298-81-7 4114
26
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
27
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
28
Captopril Approved Phase 3 62571-86-2 44093
29
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
30
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
31
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
32
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
33
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
34
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
35
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
36
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
37
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
38
Acyclovir Approved Phase 3 59277-89-3 2022
39
Ondansetron Approved Phase 3,Phase 2,Not Applicable 99614-02-5 4595
40
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
41
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
42
Panobinostat Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 404950-80-7 6918837
43
Vorinostat Approved, Investigational Phase 3,Phase 2,Phase 1 149647-78-9 5311
44
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
45
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
46
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 53-03-2 5865
47
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
48
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
49
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
50
Vincristine Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 342)
# Name Status NCT ID Phase Drugs
1 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
2 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
3 Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Terminated NCT01625455 Phase 4 Aprepitant;Placebo
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
7 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
8 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3 LBH589
9 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
10 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
11 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
12 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
15 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
16 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
17 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
18 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
19 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
20 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
21 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
22 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
23 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
24 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
25 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
26 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Active, not recruiting NCT01728805 Phase 3 Vorinostat
27 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
28 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
29 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3 lenalidomide
30 Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
31 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
32 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
33 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
34 Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
35 Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
36 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
37 Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
38 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
39 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
40 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
41 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
42 Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome Completed NCT02243579 Phase 2
43 Immunization Against Tumor Cells in Sezary Syndrome Completed NCT00099593 Phase 2
44 Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome Completed NCT00002479 Phase 2 tretinoin
45 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Completed NCT01396070 Phase 2 Brentuximab vedotin
46 Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL Completed NCT00178841 Phase 2 Rosiglitazone and Bexarotene
47 O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma Completed NCT00961220 Phase 1, Phase 2 Carmustine;O6-Benzylguanine
48 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Completed NCT00007345 Phase 2 Romidepsin
49 Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) Completed NCT00091559 Phase 2 MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
50 Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma Completed NCT00306969 Phase 1, Phase 2 bexarotene

Search NIH Clinical Center for Sezary's Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: sezary syndrome

Genetic Tests for Sezary's Disease

Anatomical Context for Sezary's Disease

MalaCards organs/tissues related to Sezary's Disease:

41
T Cells, Bone, Bone Marrow, Skin, Lymph Node, Liver, Kidney

Publications for Sezary's Disease

Articles related to Sezary's Disease:

(show top 50) (show all 66)
# Title Authors Year
1
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. ( 29947731 )
2018
2
Remarkable Advances in the Management of Mycosis Fungoides and the Sezary Syndrome. ( 28423383 )
2017
3
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. ( 28961843 )
2017
4
Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS). ( 28466385 )
2017
5
CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides. ( 28441377 )
2017
6
Transformation of Mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. ( 28533196 )
2017
7
How we treat mycosis fungoides and sezary syndrome. ( 27151889 )
2016
8
A retrospective comparative outcome analysis following systemic therapy in Mycosis Fungoides and Sezary Syndrome. ( 27649045 )
2016
9
Biopsy correlation of surface area vs single axis measurements on CT scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sezary syndrome. ( 28012157 )
2016
10
Single TCR-VI^2 evaluation discloses the circulating T cell clone in Sezary syndrome: one family fits all! ( 25733488 )
2015
11
Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. ( 25312300 )
2014
12
Molluscum contagiosum surrounded by a white halo and Sezary syndrome. ( 25186152 )
2014
13
Comprehensive analysis of PTEN status in Sezary syndrome. ( 24062018 )
2013
14
Identification of Multiple Complex Rearrangements Associated with Deletions in the 6q23-27 Region in Sezary Syndrome. ( 23698072 )
2013
15
Bilateral Hypopyon Uveitis Secondary to Mycosis Fungoides with Sezary Syndrome. ( 24131357 )
2013
16
A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. ( 23735705 )
2013
17
Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome. ( 22918164 )
2013
18
Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. ( 24335103 )
2013
19
Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome. ( 23581433 )
2013
20
Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. ( 22936659 )
2012
21
Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience. ( 22044137 )
2012
22
A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. ( 21252059 )
2011
23
Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). ( 21883142 )
2011
24
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with Oa8P-methylguanine-DNA methyltransferase and mismatch repair proteins. ( 21747120 )
2011
25
Differential patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides, Sezary syndrome and CD30(+) lymphoproliferative disorders: immunohistochemical study of 43 samples. ( 21868202 )
2011
26
The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. ( 21455551 )
2011
27
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. ( 20351328 )
2010
28
Photodynamic therapy with the silicon phthalocyanine pc 4 induces apoptosis in mycosis fungoides and sezary syndrome. ( 21197103 )
2010
29
MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. ( 20448109 )
2010
30
Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. ( 20484084 )
2010
31
Sezary syndrome: a case study of cutaneous T-cell lymphoma. ( 19349262 )
2009
32
Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update. ( 19755952 )
2009
33
Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. ( 19843862 )
2009
34
Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. ( 18832135 )
2009
35
Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. ( 18569636 )
2008
36
Assessment of delayed reporting of mycosis fungoides and Sezary syndrome in the United States. ( 18347305 )
2008
37
Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies. ( 18798522 )
2008
38
Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. ( 18314443 )
2008
39
Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. ( 17275192 )
2007
40
Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. ( 17546636 )
2007
41
Mycosis fungoides and Sezary syndrome against a human immunodeficiency virus-positive background: case report. ( 17919204 )
2007
42
Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. ( 17975162 )
2007
43
Killer cell Ig-like receptors CD158a and CD158b display a coactivatory function, involving the c-Jun NH2-terminal protein kinase signaling pathway, when expressed on malignant CD4+ T cells from a patient with Sezary syndrome. ( 17522341 )
2007
44
[KIR3DL2: a new step for the management of patients with Sezary syndrome]. ( 16962036 )
2006
45
Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. ( 15727636 )
2005
46
[Clinicomorphological characteristics of Sezary's disease and mycosis fungoides]. ( 16320688 )
2005
47
Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). ( 15305382 )
2004
48
Sezary syndrome cells unlike normal circulating T lymphocytes fail to migrate following engagement of NT1 receptor. ( 14962098 )
2004
49
Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. ( 14695224 )
2003
50
Diminished expression of the type II receptor for TGFbeta (TGFbetaRII) in T lymphocytes from patients with Sezary syndrome is not due to mutations in the receptor's poly-A tract: limitations of the standard RT-PCR in cDNA sequence analysis of homopolymeric base stretches. ( 12546068 )
2002

Variations for Sezary's Disease

ClinVar genetic disease variations for Sezary's Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.428delT (p.Phe143Serfs) deletion Pathogenic rs587776638 GRCh37 Chromosome 1, 85733584: 85733584
2 BCL10 NM_003921.4(BCL10): c.428delT (p.Phe143Serfs) deletion Pathogenic rs587776638 GRCh38 Chromosome 1, 85267901: 85267901

Cosmic variations for Sezary's Disease:

9
(show top 50) (show all 92)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5574244 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2668A>C p.T890P 10:31523999-31523999 9
2 COSM5574236 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.517C>T p.P173S 10:31510708-31510708 9
3 COSM5574238 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.752A>G p.Y251C 10:31514670-31514670 9
4 COSM44854 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.655C>A p.P219T 17:7674876-7674876 9
5 COSM44036 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.296C>T p.S99F 17:7676073-7676073 9
6 COSM44312 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.511G>A p.E171K 17:7675101-7675101 9
7 COSM45449 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.592G>C p.E198Q 17:7674939-7674939 9
8 COSM45796 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.623A>G p.D208G 17:7674908-7674908 9
9 COSM10768 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.535C>T p.H179Y 17:7675077-7675077 9
10 COSM11073 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024C>T p.R342* 17:7670685-7670685 9
11 COSM11166 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.406C>T p.Q136* 17:7675206-7675206 9
12 COSM5574229 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1918C>T p.Q640* 4:105235860-105235860 9
13 COSM42016 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4393C>T p.R1465* 4:105272774-105272774 9
14 COSM5574231 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.521C>A p.P174H 4:105234463-105234463 9
15 COSM100075 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4193T>C p.L1398P 4:105272574-105272574 9
16 COSM110772 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4474G>T p.E1492* 4:105272855-105272855 9
17 COSM1716590 STAT5B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1924A>C p.N642H 17:42207711-42207711 9
18 COSM1717514 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1492A>G p.I498V 17:42324819-42324819 9
19 COSM1155743 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1919A>T p.Y640F 17:42322464-42322464 9
20 COSM5574219 SETD1A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1211G>A p.R404H 16:30964953-30964953 9
21 COSM5104 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.392C>T p.T131I 10:87933151-87933151 9
22 COSM5159 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.733C>T p.Q245* 10:87957951-87957951 9
23 COSM23568 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.919G>A p.E307K 10:87961011-87961011 9
24 COSM3734685 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1034C>T p.S345F 20:41163944-41163944 9
25 COSM5049787 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1025A>G p.D342G 20:41163935-41163935 9
26 COSM5049788 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024G>A p.D342N 20:41163934-41163934 9
27 COSM3405078 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3487G>A p.E1163K 20:41173744-41173744 9
28 COSM3734686 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1559C>T p.S520F 20:41165499-41165499 9
29 COSM5574251 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3473G>A p.R1158H 20:41173730-41173730 9
30 COSM5613080 PIK3CA haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1609C>T p.R537* 3:179218279-179218279 9
31 COSM580 NRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.181C>A p.Q61K 1:114713909-114713909 9
32 COSM4591233 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.534G>C p.K178N 17:16165063-16165063 9
33 COSM126825 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2125C>T p.Q709* 17:16108843-16108843 9
34 COSM5574213 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3360G>C p.E1120D 17:16080448-16080448 9
35 COSM5574204 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6038C>T p.P2013L 17:16058037-16058037 9
36 COSM5574211 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6322C>T p.Q2108* 17:16057584-16057584 9
37 COSM5574208 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.76C>A p.Q26K 17:16194494-16194494 9
38 COSM532 KRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.38G>A p.G13D 12:25245347-25245347 9
39 COSM5574196 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.11845C>T p.Q3949* 12:49032050-49032050 9
40 COSM5574193 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4475G>C p.S1492T 12:49043902-49043902 9
41 COSM30358 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.7495G>A p.D2499N 12:49039283-49039283 9
42 COSM5574203 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.5923C>G p.L1975V 12:49041037-49041037 9
43 COSM5574250 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3067T>C p.Y1023H 19:17830532-17830532 9
44 COSM34214 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1715C>T p.A572V 19:17837200-17837200 9
45 COSM51374 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1533G>A p.M511I 19:17838299-17838299 9
46 COSM3734693 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1975C>T p.R659C 1:64846661-64846661 9
47 COSM5574248 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2128C>G p.L710V 1:64844877-64844877 9
48 COSM2239136 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1961A>T p.Y654F 1:64846675-64846675 9
49 COSM5574188 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2292G>T p.R764S 20:32805398-32805398 9
50 COSM1025793 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.895C>T p.R299* 20:32791682-32791682 9

Copy number variations for Sezary's Disease from CNVD:

7 (show top 50) (show all 353)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 38537 10 103280000 105830000 Deletion ACTR1A Sezary syndrome
2 38538 10 103280000 105830000 Deletion ARL3 Sezary syndrome
3 38539 10 103280000 105830000 Deletion BTRC Sezary syndrome
4 38540 10 103280000 105830000 Deletion COL17A1 Sezary syndrome
5 38541 10 103280000 105830000 Deletion CYP17A1 Sezary syndrome
6 38542 10 103280000 105830000 Deletion FGF8 Sezary syndrome
7 38543 10 103280000 105830000 Deletion LDB1 Sezary syndrome
8 38544 10 103280000 105830000 Deletion MGEA5 Sezary syndrome
9 38545 10 103280000 105830000 Deletion NEURL Sezary syndrome
10 38546 10 103280000 105830000 Deletion NFKB2 Sezary syndrome
11 38547 10 103280000 105830000 Deletion NT5C2 Sezary syndrome
12 38548 10 103280000 105830000 Deletion PCGF6 Sezary syndrome
13 38549 10 103280000 105830000 Deletion PDCD11 Sezary syndrome
14 38550 10 103280000 105830000 Deletion POLL Sezary syndrome
15 38551 10 103280000 105830000 Deletion PSD Sezary syndrome
16 38552 10 103280000 105830000 Deletion SH3PXD2A Sezary syndrome
17 38553 10 103280000 105830000 Deletion SLK Sezary syndrome
18 38554 10 103280000 105830000 Deletion SUFU Sezary syndrome
19 38555 10 103280000 105830000 Deletion TLX1 Sezary syndrome
20 38556 10 103280000 105830000 Deletion TRIM8 Sezary syndrome
21 39119 10 110240000 112960000 Deletion ADD3 Sezary syndrome
22 39120 10 110240000 112960000 Deletion DUSP5 Sezary syndrome
23 39121 10 110240000 112960000 Deletion MXI1 Sezary syndrome
24 39122 10 110240000 112960000 Deletion PDCD4 Sezary syndrome
25 39123 10 110240000 112960000 Deletion SMC3 Sezary syndrome
26 39709 10 118690000 123210000 Deletion BAG3 Sezary syndrome
27 39710 10 118690000 123210000 Deletion BRWD2 Sezary syndrome
28 39711 10 118690000 123210000 Deletion CASC2 Sezary syndrome
29 39712 10 118690000 123210000 Deletion EIF3S10 Sezary syndrome
30 39713 10 118690000 123210000 Deletion EMX2 Sezary syndrome
31 39714 10 118690000 123210000 Deletion FGFR2 Sezary syndrome
32 39715 10 118690000 123210000 Deletion GFRA1 Sezary syndrome
33 39716 10 118690000 123210000 Deletion HSPA12A Sezary syndrome
34 39717 10 118690000 123210000 Deletion INPP5F Sezary syndrome
35 39718 10 118690000 123210000 Deletion NANOS1 Sezary syndrome
36 39719 10 118690000 123210000 Deletion PRDX3 Sezary syndrome
37 39720 10 118690000 123210000 Deletion PRLHR Sezary syndrome
38 39721 10 118690000 123210000 Deletion RGS10 Sezary syndrome
39 39722 10 118690000 123210000 Deletion TIAL1 Sezary syndrome
40 40284 10 126610000 131820000 Deletion ADAM12 Sezary syndrome
41 40285 10 126610000 131820000 Deletion BCCIP Sezary syndrome
42 40286 10 126610000 131820000 Deletion CTBP2 Sezary syndrome
43 40287 10 126610000 131820000 Deletion DHX32 Sezary syndrome
44 40288 10 126610000 131820000 Deletion DOCK1 Sezary syndrome
45 40289 10 126610000 131820000 Deletion MGMT Sezary syndrome
46 40290 10 126610000 131820000 Deletion MKI67 Sezary syndrome
47 40291 10 126610000 131820000 Deletion MMP21 Sezary syndrome
48 40292 10 126610000 131820000 Deletion PTPRE Sezary syndrome
49 40293 10 126610000 131820000 Deletion ZRANB1 Sezary syndrome
50 42175 10 29840000 33170000 Deletion ARHGAP12 Sezary syndrome

Expression for Sezary's Disease

Search GEO for disease gene expression data for Sezary's Disease.

Pathways for Sezary's Disease

Pathways related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 BCL10 CD28 CTLA4 IFNG IFNGR2 IL2
2
Show member pathways
13.68 CD28 IFNG IFNGR2 IL2 IL2RA IL4
3
Show member pathways
13.52 IFNG IFNGR2 IL2 IL2RA IL4 IL5
4
Show member pathways
13.42 CD28 IL2 IL2RA IL4 IL5 IL7
5
Show member pathways
13.37 IFNG IFNGR2 IL2 IL2RA IL4 IL5
6
Show member pathways
13.29 CD28 IL2 IL2RA IL4 IL5 IL7
7 12.87 IFNG IFNGR2 IL2 IL2RA IL4 IL5
8
Show member pathways
12.86 IL2 IL2RA IL4 IL7 TNFRSF1B
9
Show member pathways
12.84 BCL10 IFNG IFNGR2 IL2 IL2RA IL4
10
Show member pathways
12.83 CD28 IFNG IFNGR2 IL2 IL2RA IL4
11
Show member pathways
12.69 IFNG IFNGR2 IL2 IL2RA IL4 IL5
12
Show member pathways
12.67 BCL10 CD28 CTLA4 IFNG IFNGR2 IL2
13
Show member pathways
12.53 IFNG IFNGR2 IL2 IL4 KIR3DL2
14
Show member pathways
12.5 IFNG IFNGR2 IL2 IL2RA IL4 IL5
15 12.47 BCL10 CD28 CTLA4 IFNG IL2 IL2RA
16
Show member pathways
12.42 BCL10 CD28 CTLA4 IL2 IL2RA
17
Show member pathways
12.41 BCL10 CD28 CTLA4 IFNG IL2 IL4
18
Show member pathways
12.32 CD28 IFNG IFNGR2 IL2 STAT4 TLR9
19 12.23 BCL10 IFNG IFNGR2 TLR9
20
Show member pathways
12.22 CD28 IL2 IL2RA STAT4 TRB
21
Show member pathways
12.18 IFNG IFNGR2 IL4 TLR9
22
Show member pathways
12.13 IFNG IFNGR2 IL2 IL2RA IL4 IL5
23
Show member pathways
12.05 IL2 IL2RA IL5 TLR9
24
Show member pathways
12.05 IFNG IL2 IL2RA IL4 STAT4 TRB
25 11.98 CD28 IFNG IL2 IL2RA IL4 IL5
26 11.95 IFNG IFNGR2 IL2 IL2RA STAT4
27 11.93 IL2RA IL4 IL5 IL7
28 11.86 IFNG IL2 IL2RA IL4 IL5 IL7
29 11.84 IFNG IL2 IL4 IL5
30 11.82 CD28 CTLA4 IFNG
31
Show member pathways
11.81 CTLA4 IFNG IL2 IL2RA IL4 IL5
32 11.73 IFNG IL2 TLR9
33
Show member pathways
11.7 IFNG IL2 IL2RA STAT4
34
Show member pathways
11.68 IL2 IL2RA IL4
35 11.58 CD28 TNFRSF1B TRB
36
Show member pathways
11.54 IFNG IFNGR2 TNFRSF1B
37 11.39 IFNG IL4 IL5 IL7
38 11.37 CD28 CTLA4 IL2 TRB
39
Show member pathways
11.29 IFNG IL2RA STAT4
40 11.28 CD28 IFNG IL2 IL2RA STAT4
41 11.28 IFNG IL2 IL4 IL5 IL7 TRB
42 11.27 IFNG IL2 IL4 IL5
43 11.16 CD28 IFNG IL2 IL2RA IL4 IL5
44 10.69 CD28 IFNG IL2 IL2RA IL4 IL5

GO Terms for Sezary's Disease

Cellular components related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 IFNG IL2 IL4 IL5 IL7 MIR223
2 protein complex involved in cell adhesion GO:0098636 8.62 CD28 CTLA4

Biological processes related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 DPP4 IFNG IL2 IL5 IL7
2 regulation of signaling receptor activity GO:0010469 9.92 IFNG IL2 IL4 IL5 IL7
3 adaptive immune response GO:0002250 9.89 BCL10 CTLA4 IFNG IL2
4 cell surface receptor signaling pathway GO:0007166 9.83 CD28 IFNG IFNGR2 IL2RA TNFRSF1B
5 negative regulation of inflammatory response GO:0050728 9.79 IL2 IL2RA TNFRSF1B
6 cytokine-mediated signaling pathway GO:0019221 9.76 IFNGR2 IL2 IL2RA IL4 IL5 IL7
7 T cell costimulation GO:0031295 9.71 CD28 CTLA4 DPP4
8 positive regulation of T cell proliferation GO:0042102 9.71 CD28 IL2 IL2RA IL4
9 humoral immune response GO:0006959 9.69 CD28 IFNG IL7
10 T cell activation GO:0042110 9.65